Document is current

Article History

Accepted: 7 February 2024

First Online: 12 March 2024

Competing interests

: N.D. has received consulting fees, speaker fees or grants from Arthrosi, AstraZeneca, Dyve Biosciences, Hikma, Horizon, JPI, JW Pharmaceutical Corporation, LG Chem, Novartis, PK Med, Protalix, PTC Therapeutics, Selecta and Unlocked Labs, outside the submitted work. F.L. has received consulting fees from Horizon Biosciences, Mayoly Spindler, Novartis, Olatec and SOBI-Selecta, and unrestricted grants for the European Crystal Network workshops from Arthrosi, AstraZeneca, Dyve Biosciences, Horizon Biosciences, Mayoly Spindler and Olatec, outside the submitted work. A.G has served as consultant SOBI, PK Med and serves on a data monitoring committee for Atom Bioscience. J.L.J. is a Trustee of the American College of Cardiology and a board member of Imbria Pharmaceuticals; has received grant support from Abbott Diagnostics, Applied Therapeutics, HeartFlow, Innolife and Novartis; has received consulting income from Abbott Diagnostics, AstraZeneca, Beckman Coulter, Jana Care, Janssen, Novartis, Prevencio, Quidel and Roche Diagnostics; and participates in clinical end point committees/data safety monitoring boards for AbbVie, Abbott, Bayer, Siemens, Pfizer and Takeda, outside the submitted work. R.T. has served or serves as a consultant for Acquist Therapeutics, Allena, AstraZeneca, Atom Bioscience, Fortress/Urica, Generate Biomedicines, Horizon Therapeutics, LG Chem, Selecta Biosciences and Synlogic, and was a previous recipient of a research grant from AstraZeneca. R.T. serves as the non-salaried President of the G-CAN (Gout, Hyperuricemia and Crystal-Associated Disease Network) research society; over its 9 years of existence, G-CAN annually has received unrestricted arms-length grant support from pharma donors. D.J.W. serves on a data monitoring committee for Novo Nordisk, outside the submitted work. H.K.C. reports research support from Ironwood and Horizon, and consulting fees from Horizon, Ironwood, Kowa, Selecta, Takeda and Vaxart. M.E.S. receives research funding from AbbVie, Angion, Cabaletta, EMD-Serono, Gilead, Novartis, Otsuka and Roche; serves on scientific advisory boards for Calliditas, Mallinckrodt, Novartis, Travere and Vera; and serves as a DSMB member for Alpine Immunosciences. T.P. has received consulting and speaker fees from Novartis and consulting and research grants from Horizon Pharmaceuticals. C.Y., J.F., N.M. and A.A. declare no competing interests.